The order uses a compact legal architecture built on three main devices.

1. Classification by declaration. Section 4 makes a formal declaration that specified substances in Schedule 1 are "substances to which section 36 of the Poisons Act 1971 applies" (s 4(1)). The order therefore functions as a classificatory instrument, expanding or consolidating the set of substances that fall within the scope of an existing statutory provision in the Poisons Act 1971, rather than amending the Act itself.

2. Cross‑reference to the Poisons List. Several Schedule 1 entries include, in parentheses, a capital letter “S” and a numeral, for example “(S4)”. The order provides that such notation is a reference to that substance when included in the correspondingly numbered Schedule of the Poisons List (s 4(2)). This is an explicit mechanism to ensure consistency between the order and the Poisons List, and to avoid duplication or conflict in classification between instruments.

3. Repeal of prior orders. Section 5 and Schedule 2 revoke an earlier set of declared‑substances orders and amendment orders (Schedule 2). The revocations remove prior parallel instruments from the statute book, consolidating the list in this 2017 order.

The order also brings interpretive rules into play by applying the Acts Interpretation Act 1931, treating the order as if it were by-laws (s 3). That affects how headings, singular/plural expressions, citations, and possibly other interpretive presumptions are applied to the instrument. The order’s commencement rule is simple: it takes effect on the day its making is notified in the Gazette (s 2); the instrument records that it was notified on 31 December 2017.

Substantively, Schedule 1 sets out individual entries, some with chemical synonyms, some with generic headings (for example “Anabolic and androgenic steroidal agents, including those separately specified in Schedule 4 of the Poisons List (S4)”), and some that call out exceptions or cross‑listings (for example the entry for benzodiazepine derivatives excluding certain named drugs, and separate entries for those named drugs). The Schedule therefore combines broad categories and individual named substances into a single declared list.

The order identifies substances rather than persons, but its legal effect attaches to conduct involving those substances because it declares them to be subject to section 36 of the Poisons Act 1971 (s 4(1)). Consequently, the universe of affected parties is the set of persons and entities that, in practice, manufacture, import, export, supply, store, prescribe, administer, possess, test, research on, or otherwise deal with substances listed in Schedule 1. The order does not enumerate those classes of persons itself; it creates an effect that reaches them through the parent Act.

Practically, the following actor groups are implicated by the instrument’s classifications, with the caveat that the specific duties and constraints that bind each group are determined by section 36 and other provisions of the Poisons Act 1971 and by any implementing administrative instruments or guidance:

• Manufacturers and distributors of pharmaceuticals, peptides, hormones, anabolic agents, stimulants, sedatives, and related chemical products that match items in Schedule 1. Schedule 1 includes anabolic and androgenic steroidal agents (item 1), a range of benzodiazepines and hypnotics (for example items 5, 7, 16, 20, 21, 27, 61, 64, 79, 83), stimulants and precursors such as ephedrine, pseudoephedrine and cathine (items 13, 30, 74), opioids and analgesics such as codeine and tramadol (items 24, 81), and peptide/protein growth factors and analogues such as somatropin, erythropoietins, GHRHs and GHRPs (items 31-35, 40-49, 72, 76).

• Importers and customs brokers who handle shipments containing any named substances or products containing them, because a change in declared status will affect border processing to the extent the relevant customs and biosecurity practices reference the Poisons Act status.

• Pharmacies, hospital pharmacies, clinicians and prescribers who dispense, prescribe, or administer drugs that appear in Schedule 1. Several entries are marked S4, indicating a Poisons List schedule relationship that may affect supply classification (s 4(2); Schedule 1 entries marked S4).

• Laboratories and forensic analysts that test samples for controlled substances, and research laboratories that possess or use listed peptides, hormones or steroids either for scientific study or product development.

• Retailers and wholesalers that supply over‑the‑counter products containing constituents listed in Schedule 1; the presence of S4 markings in Schedule 1 signals that certain products may already be listed on the Poisons List, thereby potentially changing availability and supply chains.

• Sports organisations, teams, and persons involved in performance or competitive contexts where substances such as anabolic agents, erythropoietins, growth hormones and selective androgen receptor modulators are relevant.

Because the order itself operates by reference to section 36 of the Poisons Act 1971, any obligations, prohibitions, registration, licensing, storage or record‑keeping requirements, and penalties that apply to these actor groups depend on the content of section 36 and related statutory and administrative instruments. The order does not specify those obligations, so the practical compliance impact for each group must be determined by interrogating the Poisons Act 1971 and any implementing rules that operationalise section 36 for these declared substances.

The order is limited in form and scope: it declares which substances are to be treated as within the scope of section 36 of the Poisons Act 1971 (s 4(1)), and it cross‑references Poisons List schedules where indicated (s 4(2)). It does not itself set out duties, rights, processes for decision making, licensing, exemptions, defences, record‑keeping standards, or appeal rights. Those operational elements remain vested in the Poisons Act 1971 and any subordinate instruments or administrative practice that implement section 36.

Accordingly, the key legal duty created by the order is classificatory,therefore the immediate legal right or duty for any person flows from the fact of classification. Concretely:

• Duty (implicit and contingent): Persons who deal in the substances listed in Schedule 1 become subject to whatever regulatory obligations, restrictions or prohibitions apply under section 36 of the Poisons Act 1971 to substances within its scope. The order makes the link explicit by declaration (s 4(1)).

• Right (implicit and contingent): Persons affected retain whatever rights are preserved under the Poisons Act 1971 to seek licences, approvals, exemptions or to contest administrative decisions about the application of the Act to particular conduct, to the extent those procedural rights exist under the parent Act. The order does not create or remove procedural rights itself.

• Interpretive regime: The Acts Interpretation Act 1931 applies to the interpretation of the order as if it were by‑laws (s 3). That affects statutory interpretation conventions that determine how duties and rights are read into the declared list, for example, in relation to singular/plural, headings, inclusive definitions and the application of provisions by reference.

• Cross‑instrument rights/duties from the Poisons List: Where a Schedule 1 entry includes an “S” and numeral, the order explicitly ties that notation to the corresponding schedule of the Poisons List (s 4(2)). This produces an interaction such that rights or restrictions which are expressed in the Poisons List in relation to the relevant schedule may be relevant to determining supply, labelling, or access rules for those substances.

Because the order does not itself prescribe the content of those obligations, practitioners must consult section 36 of the Poisons Act 1971 and any operative subordinate instruments to identify concrete duties such as requirements to hold licences, maintain records, observe labelling and packaging standards, or face prohibitions and penalties. The order triggers the application of that wider regime to the enumerated substances, it does not replace or restate it.

The order contains no standalone penalties, offence‑provisions or enforcement mechanisms. It is declaratory in nature: it attaches named substances to the operation of section 36 of the Poisons Act 1971 (s 4(1)). Any penalties, sanctions, licensing refusals, seizure powers, inspection regimes or compliance notices that might apply to conduct involving those substances are matters for the Poisons Act 1971 and implementing administrative instruments, not for this order itself.

Because the order does not reproduce section 36 or any enforcement text, the instrument does not specify:

• Which actions constitute offences in relation to a listed substance;

• The nature or range of penalties, fines, imprisonment or civil remedies;

• The administrative pathway for issuing licences, permits or exemptions;

• The identity of the enforcing agency or the powers of inspectors.

Enforcement practice therefore requires, in each instance, reference back to the primary legislation and subsidiary instruments that operationalise section 36 and enforcement under the Poisons Act 1971. The only enforcement‑related legal effect visible on the face of the order is the creation of legal proximity: a substance that is declared in Schedule 1 becomes subject to the enforcement architecture attached to section 36. The order itself does not extend or create enforcement powers beyond that link.

Practitioners should note that Schedule 1 contains multiple entries marked “(S4)”, and section 4(2) ties that mark to the corresponding numbered Schedule of the Poisons List. Where enforcement or supply restrictions are framed by reference to Poisons List schedules, the S4 notation in this order is an explicit signpost. However the order does not itself authorise enforcement agencies or specify the mode of enforcement; it only supplies the declaratory basis for enforcement actions predicated on the scope of section 36 as applied to the named substances.

The order expressly engages with two other statutory instruments by textual reference.

1. Poisons Act 1971. The declared effect of the order is to make specified substances "substances to which section 36 of the Poisons Act 1971 applies" (s 4(1)). This is an explicit point of interaction: the order does not stand alone; it operates by reference to an identified provision of the parent Act. The exact legal consequences of that interaction depend entirely on the content and application of section 36 and any other provisions in the Poisons Act 1971. The order does not restate or amend section 36, it links the enumerated substances to it.

2. Poisons List. The order uses the notation "(S4)" in certain Schedule 1 entries and provides that a reference in Schedule 1 to a substance by name followed, in parentheses, by a capital letter "S" and a numeral is a reference to that substance when included in the correspondingly numbered Schedule of the Poisons List (s 4(2)). This creates a direct cross‑reference: entries marked with an S and numeral are to be read in the context of the Poisons List’s numbered schedules. That means the order and the Poisons List are intended to be read together for those items.

3. Acts Interpretation Act 1931. The order declares that the Acts Interpretation Act 1931 applies to the interpretation of the order as if the order were by‑laws (s 3). This has the effect of importing interpretive principles and rules from that Act into the reading of the order. It therefore affects how cross‑references, the meaning of expressions, commorientes, and other interpretation matters are resolved when construing the declared list.

4. Repealed subordinate instruments. The order revokes earlier Poisons (Declared Restricted Substances) Orders and amendment orders listed in Schedule 2 (s 5 and Schedule 2). The effect of those revocations is that the earlier instruments no longer operate as separate sources of declaration; their content is superseded by the 2017 order as displayed. That consolidation can have practical implications if prior instruments contained differing lists or transitional provisions; those documents are specifically revoked by Schedule 2.

The order does not expressly interact with customs, biosecurity, therapeutic goods/regulatory regimes, criminal law, workplace safety or other statutes on its face. Where such interactions occur in practice, they will be derivative: for example, customs control of imported goods may take account of a substance’s declared status under the Poisons Act 1971, but the order itself does not create customs obligations. To determine cross‑system effects, users must cross‑check the Poisons Act and the Poisons List, together with any administrative or regulatory instruments in other statutory regimes that reference the Poisons Act classification.

The order provides a clear single‑step amendment/consolidation history on its face. It revokes the following instruments by name in Schedule 2 (s 5; Schedule 2):

• Poisons (Declared Restricted Substances) Order 1990 (No. 189 of 1990)

• Poisons (Declared Restricted Substances) Order 1998 (No. 15 of 1998)

• Poisons (Declared Restricted Substances) Order (No. 2) 1998 (No. 73 of 1998)

• Poisons (Declared Restricted Substances) Amendment Order 2010 (No. 120 of 2010)

• Poisons (Declared Restricted Substances) Amendment Order 2014 (No. 38 of 2014)

• Poisons (Declared Restricted Substances) Amendment Order 2015 (No. 60 of 2015)

The instrument’s text also records the Gazette notification date: "Notified in the Gazette on 31 December 2017." The order commences on the day on which its making is notified in the Gazette (s 2). Together, these details indicate that the 2017 Order replaced and consolidated prior declared‑substance orders and amendments listed in Schedule 2 with effect from its publication date.

No other amendments to this order are shown in the text provided. The order itself contains no internal amendment provision; it is a standalone instrument that both declares the substances in Schedule 1 and removes the prior instruments listed in Schedule 2. Because the Acts Interpretation Act 1931 applies for interpretation, any future amendments, revocations or consolidations will be undertaken in accordance with the procedural and interpretive rules relevant to by‑laws as invoked by s 3.

Practitioners should note that the order is explicitly a replacement for earlier subordinate instruments; that can matter when tracing historical classification or when assessing the point at which a particular substance was first declared subject to section 36 of the Poisons Act 1971, since the revocations in Schedule 2 remove the earlier instruments from current operation.

The order as provided contains no record of litigation, judicial interpretation, contested application, or references to cases. It is a statutory instrument that declares a list of substances and revokes earlier orders; the text does not record any court decisions or legal challenges to its content.

Because the order delegates substantive duties and penalties to section 36 of the Poisons Act 1971 by declaration, litigation that relates to the practical application of this order,such as disputes about whether a particular product falls within the Schedule 1 description, prosecution or defence under the Poisons Act, or administrative review of decisions that apply section 36 to a declared substance,would arise under the parent Act rather than within the order itself. The order does not cite any existing cases, and no cases are named or summarised in the instrument.

If litigation exists that interprets the effect of declaring substances under section 36, it will be found in decisions construing the Poisons Act 1971, decisions addressing the Poisons List, or cases concerning administrative decisions that rely on the order to classify substances. Those materials are not reproduced in the text of this order, and the order contains no internal litigation history.

Several features of the order can create practical pitfalls for practitioners who assume the order stands alone or is self‑contained.

1. Declaratory, not prescriptive. The order does not itself prescribe supply, licensing or penalty rules. It declares substances to which section 36 applies (s 4(1)). A common error would be to treat the order as if it sets out the operational regime; it does not. Any compliance obligation must be checked against the Poisons Act 1971 and any subordinate instruments that implement section 36.

2. S4 notation is a cross‑reference, not a standalone rule. Items in Schedule 1 marked "(S4)" are references to the Poisons List schedule of that number (s 4(2)). The order’s S4 marking does not itself state what the Poisons List says about that substance; it simply ties that Schedule 1 entry to the Poisons List’s corresponding schedule. For example, "Anabolic and androgenic steroidal agents, including those separately specified in Schedule 4 of the Poisons List (S4)" (Schedule 1, item 1) combines a general heading with an express link to the Poisons List. Practitioners must read the Poisons List in parallel.

3. Mixed specificity and generality. Schedule 1 contains both broad category entries (for example "Anabolic and androgenic steroidal agents" at item 1, and "Growth hormone‑releasing hormones (GHRHs)" at item 42) and narrowly named chemicals (for example "Trenbolone (S4)" at item 82). The co‑existence of categories and named substances may create ambiguity for product classification at the margins, for example where a novel derivative is not named but could be captured by a broad category. Because the order applies interpretive rules under the Acts Interpretation Act 1931 (s 3), those rules will guide how to reconcile categories and specific names, but the order does not itself resolve borderline cases.

4. Synonyms and alias language. Many Schedule 1 entries include aliases or "otherwise known as" formulations (for example "Clostebol (otherwise known as 4‑chlorotestosterone)" at item 23). Practitioners must map commercial or chemical names used in supply chains against both the listed names and synonyms to avoid misclassification.

5. Exceptions within entries. Some entries carve out exceptions while other entries list the same substances separately. For example Schedule 1 item 5 covers "Benzodiazepine derivatives not elsewhere specified in this Schedule (except clonazepam and midazolam)" while clonazepam and midazolam appear separately at items 21 and 61. That drafting pattern requires careful reading to avoid double counting or misreading where a substance is both generally and specifically addressed.

6. Duplication and exclusion language. Schedule 1 includes both specific entries and catch‑all language such as "Erythropoietins except when separately specified in this Schedule" (item 34), alongside individual erythropoietin entries (items 31-33). That sort of drafting can produce unexpected classification outcomes for related molecules or formulations.

7. No transition provisions. The order revokes earlier instruments listed in Schedule 2 (s 5). The order does not set out transitional arrangements on its face, for example for stocks in trade, pending applications, or licences issued under the revoked orders. Those transitional matters, if any, must be governed by the Poisons Act 1971, by the repealed instruments prior to revocation (subject to their revocation), or by administrative practice. The order itself is silent.

8. Narrow textual commencement. The order takes effect on the day its making is notified in the Gazette (s 2). The document records a notification date of 31 December 2017. Parties that relied on earlier instruments must note the date of effect precisely because the revocations in Schedule 2 operate from the commencement date.

9. No enforcement detail in the instrument. Because the order does not set out penalties or inspection powers, a practitioner or compliance officer cannot construct a full compliance plan using only the order. The order is a pointer; the substantive compliance obligations are to be found elsewhere.

In short, the main gotchas are that the order is declaratory and cross‑referential, it mixes generic and specific drafting, it uses S‑numeral cross‑references to the Poisons List, and it revokes prior instruments without providing transitional rules on its face. Each of those features increases the need to consult the Poisons Act 1971, the Poisons List, and any administrative guidance or licences that the enforcement agency issues.

Because the order itself is limited to declaring which substances fall under section 36 of the Poisons Act 1971 (s 4(1)), compliance is necessarily a two‑step exercise: identify scope under the order, then determine the operational obligations under the Poisons Act and any implementing instruments.

A practical compliance checklist, grounded in the structure of this order, is as follows:

1. Map inventory against Schedule 1. Compare all chemical, commercial and trade names used in product labels, formulations, research reagents, import/export documentation and purchase orders against the Schedule 1 entries, including synonyms and "otherwise known as" aliases (see Schedule 1 entries such as items 23, 38, 63). Pay special attention to items marked "(S4)" and to entries that use broad category language (for example item 1 and items 42-45), because broad category entries may catch derivatives and analogues.

2. Consult the Poisons List where items are marked S‑numeral. The order explicitly links the S4 notation to the corresponding Schedule of the Poisons List (s 4(2)). For items with that notation, read the Poisons List schedule to determine how that list treats the substance, and whether any specific supply, labelling or access rules apply to the substance in that Poisons List schedule.

3. Read section 36 of the Poisons Act 1971 and related provisions. The order attaches the listed substances to the legal effect of section 36 (s 4(1)). The concrete obligations and potential penalties arise from that Act and any implementing regulations, licences or guidance. Identify whether section 36 establishes licensing requirements, offences for possession or supply, record‑keeping obligations, or storage conditions, and ensure your operational controls reflect those rules.

4. Review licences, permits and existing approvals. If your organisation holds licences, approvals, or pending applications under the earlier revoked instruments listed in Schedule 2, confirm whether those instruments were replaced or whether your licences remain valid. The order revokes prior instruments (s 5; Schedule 2) and commences on Gazette notification (s 2); administrative practice will determine transitional arrangements, if any.

5. Update supply chain processes. For suppliers, wholesalers and retailers, ensure procurement notices, vendor declarations, customs documentation and shelf life/stock protocols reflect the reclassification. For importers, update customs and biosecurity filings where classification under the Poisons Act is a material factor in declaring goods.

6. Update clinical and dispensing protocols. For clinicians and pharmacists who prescribe, dispense or administer medicines, amend formularies and stock inventories to flag Schedule 1 substances. Items such as benzodiazepines, codeine, tramadol, and other listed agents appear in Schedule 1 and may interact with dispensing policies, even though the order itself does not state dispensing rules.

7. Labelling, storage and records. Although the order does not stipulate specific labelling or storage standards, the fact that a substance is declared to fall under the Poisons Act means those practical aspects may be regulated by the parent Act or by associated guidance. Establish secure storage, chain‑of‑custody practices and clear labelling pending confirmation of exact statutory requirements.

8. Seek legal and regulatory confirmation. Because the order is a declaratory instrument, obtain legal advice that reads the order together with the Poisons Act 1971 and any regulations, administrative determinations or guidance published by the enforcing authority. Confirm whether existing products or research uses require new licences or notifications.

9. Monitor for administrative guidance and enforcement activity. The order’s effect depends on how the enforcing agency applies section 36 to the newly declared substances. Monitor guidance, enforcement alerts, and licensing practice that follow the order’s commencement.

10. Train staff and record risk decisions. Document the steps taken to map inventory to Schedule 1, the interpretation applied to ambiguous items, and the legal advice obtained. Train procurement, pharmacy, laboratory and compliance personnel to escalate questions about borderline substances, given the order’s mix of categories and specific names.

In every step, remember that the order itself does not impose procedural rules; it only declares list membership under section 36. Compliance therefore requires reconstituting the regulatory picture by consulting the Poisons Act 1971, the Poisons List where relevant, and agency guidance.